Wet Age-Related Macular Degeneration
Ophthalmology
5
Pipeline Programs
3
Companies
3
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Qilu PharmaceuticalChina - Jinan
2 programs1
1
AfliberceptPhase 31 trial
lucentisPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Qilu PharmaceuticalAflibercept
Qilu Pharmaceuticallucentis
Molecular PartnersMP0112
Clinical Trials (3)
Total enrollment: 32 patients across 3 trials
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
Start: Aug 2019Est. completion: Jan 2022
Phase 3Completed
Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD
Start: Dec 2017Est. completion: Apr 2019
Phase 1Completed
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
Start: Mar 2010Est. completion: Nov 201032 patients
Phase 1Terminated
Related Jobs in Ophthalmology
Lead Data Manager
Genomics
Remote
10h ago
Cleanroom and Laboratory Technician
SAB BIO
10h ago
Material Handler - 8 Hour Day Shift
Pfizer
United States - Kansas - McPherson
Yesterday
Senior Process Technician - Rotating 2nd Shift
Pfizer
United States - Massachusetts - Andover
Yesterday
$27 - $45/hr
Staff Equipment and Systems Engineer
Johnson & Johnson
Plymouth, Minnesota, United States of America
Yesterday
$94K - $152K/yr
APAC Regulatory Affairs Manager
Johnson & Johnson
Singapore, Singapore
Yesterday
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space